Responsiveness to vedolizumab therapy in ulcerative colitis is associated with alterations in immune cell-cell communications

ABSTRACT: Ulcerative colitis (UC) is a major subtype of inflammatory bowel disease (IBD), a spectrum of chronic intestinal disorders caused by dysregulated immune responses to gut microbiota. Although transcriptional and functional changes in a number of immune cell types have been implicated in the pathogenesis of IBD, the cellular interactions and signals that drive these changes have been less well-studied. Moreover, the precise mechanisms of action underlying many biologic therapies, including the anti-47 integrin antagonist vedolizumab, remain incompletely understood. Our study aimed to explore possible additional mechanisms through which vedolizumab acts.

ORGANISM(S): Homo sapiens

PROVIDER: GSE228165 | GEO | 2023/06/15

REPOSITORIES: GEO